Palifermin

What is Palifermin?

Palifermin is a medication classified as a recombinant human keratinocyte growth factor (KGF). It is a modified version of the naturally occurring protein that plays a crucial role in the growth and repair of various epithelial tissues throughout the body. Developed to address a significant side effect of certain cancer treatments, Palifermin acts by stimulating the proliferation, differentiation, and migration of epithelial cells.

Its primary medical use is to prevent or reduce the severity of severe oral mucositis, a painful inflammation and ulceration of the mucous membranes in the mouth and throat. This condition is a common and debilitating complication for patients undergoing high-dose chemotherapy and radiation, particularly those preparing for hematopoietic stem cell transplantation (HSCT). Palifermin was previously marketed under the brand name Kepivance.

How Does it Work?

The mechanism of action for Palifermin centers on its ability to mimic and enhance the effects of endogenous keratinocyte growth factor. KGF receptors are predominantly found on the surface of epithelial cells, including those lining the oral cavity and gastrointestinal tract. When Palifermin binds to these receptors, it triggers a cascade of intracellular signals that promote cell growth, repair, and protection.

In the context of cancer treatment, high-dose chemotherapy and radiation therapy can cause significant damage to rapidly dividing cells, including the healthy epithelial cells of the mouth and gut. By administering Palifermin, these epithelial cells are stimulated to proliferate more rapidly and become more resilient, thereby strengthening the mucosal barrier. This protective effect helps to mitigate the cytotoxic impact of cancer treatments, reducing the incidence and severity of oral mucositis and facilitating faster recovery of the damaged tissues.

Medical Uses

The main indication for Palifermin is the prevention of severe oral mucositis in patients with hematologic malignancies who are receiving myeloablative therapy requiring hematopoietic stem cell transplantation. This patient population faces a high risk of developing severe oral mucositis, which can lead to intense pain, difficulty eating and drinking, increased risk of infection, and potential delays in cancer treatment.

By significantly reducing the incidence, duration, and severity of this debilitating side effect, Palifermin contributes to improved patient comfort and quality of life during a challenging treatment period. It allows patients to maintain better nutritional intake, reduces the need for parenteral nutrition, and may decrease the use of opioid analgesics for pain management associated with mucositis.

Dosage

The recommended dosage for Palifermin is typically 60 micrograms per kilogram of body weight (mcg/kg) administered once daily via intravenous (IV) infusion. The treatment regimen usually involves a total of six doses:

• Three daily doses given prior to the start of the myelotoxic conditioning regimen (e.g., on days -3, -2, -1 before conditioning).
• Three daily doses given after the hematopoietic stem cell infusion (e.g., on days +1, +2, +3 after HSCT).

It is crucial to administer Palifermin at least 24 hours after and 24 hours before cytotoxic chemotherapy or full-body radiation to avoid potential interactions that could reduce its protective effect. The infusion should be given slowly, over approximately 15 minutes. Proper timing is essential to allow the epithelial cells to respond and become more resistant before exposure to the damaging effects of chemotherapy and radiation.

Side Effects

Like all medications, Palifermin can cause side effects, although not everyone experiences them. Common side effects often include:

• Skin reactions such as rash, erythema (redness), pruritus (itching), and skin discoloration. These are usually mild to moderate and transient.
• Oral dysesthesia, which can manifest as altered taste sensation or tingling in the mouth.
• Edema (swelling), particularly peripheral edema.
• Fever.
• Transient elevation of serum amylase and lipase levels, which typically return to normal without intervention.

More serious, though rare, side effects may include hypersensitivity reactions. Due to its growth-promoting properties, there is a theoretical concern about the potential for Palifermin to stimulate the growth of existing squamous cell carcinomas, although this has not been definitively established in clinical trials for its approved indication. Patients should discuss their full medical history with their healthcare provider before starting treatment.

Drug Interactions

Specific drug interaction studies with Palifermin are limited. However, due to its mechanism of action, it is important to avoid administering Palifermin concurrently with chemotherapy or radiation therapy. As mentioned in the dosage section, a minimum 24-hour interval between Palifermin administration and the start or end of myelotoxic conditioning regimens is recommended.

There are no known contraindications or significant interactions reported with common immunosuppressants or other supportive care medications typically used in the context of hematopoietic stem cell transplantation. Patients should always inform their healthcare provider about all medications, supplements, and herbal products they are taking to ensure safe and effective treatment with Palifermin.

FAQ

What is oral mucositis?

Oral mucositis is a painful inflammation and ulceration of the mucous membranes lining the mouth and throat. It is a common and severe side effect of certain cancer treatments, particularly high-dose chemotherapy and radiation.

Who is Palifermin for?

Palifermin is specifically approved for patients with blood cancers (hematologic malignancies) who are undergoing high-dose chemotherapy and/or radiation therapy followed by hematopoietic stem cell transplantation, to prevent severe oral mucositis.

Is Palifermin a chemotherapy drug?

No, Palifermin is not a chemotherapy drug. It is a supportive care medication designed to mitigate the side effects of cancer treatments, rather than directly treating cancer itself.

How is Palifermin administered?

Palifermin is administered as an intravenous (IV) infusion, typically over about 15 minutes, for a total of six doses spread out before and after the stem cell transplant.

Products containing Palifermin are available through trusted online pharmacies. You can browse Palifermin-based medications at ShipperVIP or Medicenter.

Summary

Palifermin is an essential supportive care medication that significantly improves the experience of patients undergoing intense cancer treatments. As a recombinant human keratinocyte growth factor, it works by stimulating the growth and repair of epithelial cells, thereby protecting the delicate mucous membranes of the mouth from the damaging effects of high-dose chemotherapy and radiation. Its primary role is to prevent severe oral mucositis in patients undergoing hematopoietic stem cell transplantation, reducing pain, improving quality of life, and helping ensure the continuity of critical cancer therapies. Understanding its mechanism, proper dosage, and potential side effects is crucial for its safe and effective use in oncology.